Evidence map›Paper›PMID 37686418›Full record

ArticleInternational journal of molecular sciences2023

Differences in Physico-Chemical Properties and Immunological Response in Nanosimilar Complex Drugs: The Case of Liposomal Doxorubicin.

Dorelia Lipsa, Davide Magrì, Giacomo Della Camera, Rita La Spina, Claudia Cella, Irantzu Garmendia-Aguirre, Dora Mehn, Ana Ruiz-Moreno, Francesco Fumagalli, Luigi Calzolai and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dorelia LipsaEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Davide MagrìEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.ORCID 0000-0003-3790-5332
Giacomo Della CameraEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Rita La SpinaEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Claudia CellaEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.ORCID 0000-0002-9210-0775
Irantzu Garmendia-AguirreEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Dora MehnEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Ana Ruiz-MorenoEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.ORCID 0000-0002-2657-645X
Francesco FumagalliEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Luigi CalzolaiEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.
Sabrina GioriaEuropean Commission, Joint Research Centre (JRC), 21027 Ispra, Italy.ORCID 0000-0001-7150-9523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to highlight the impact of physicochemical properties on the behaviour of nanopharmaceuticals and how much carrier structure and physiochemical characteristics weigh on the effects of a formulation. For this purpose, two commercially available nanosimilar formulations of Doxil and their respective carriers were compared as a case study. Although the two formulations were "similar", we detected different toxicological effects (profiles) in terms of in vitro toxicity and immunological responses at the level of cytokines release and complement activation (iC3b fragment), that could be correlated with the differences in the physicochemical properties of the formulations. Shedding light on nanosimilar key quality attributes of liposome-based materials and the need for an accurate characterization, including investigation of the immunological effects, is of fundamental importance considering their great potential as delivery system for drugs, genes, or vaccines and the growing market demand.

Indexed as

DoxorubicinPolyethylene GlycolsExcipientsLiposomesDoxorubicinExcipientsliposomal doxorubicinLiposomesPolyethylene Glycolscomplement activationcytokinesDoxildoxorubicinendotoxininflammationliposomenanomedicinesparticle size distributionsafety assessment

Identifiers

PMID37686418
PMCPMC10487543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.